Immuneering Corp (IMRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Immuneering Corp (IMRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Grant C. Bo

Event · Exec change
Person
Grant C. Bogle, MBA
Title
member of the Company's Board as a Class III Director
Action
appointed
Effective
November 9, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 9, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$IMRX
Neutral
high confidence
Mentioned
$IMRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMRXNeutralLow
01

Why it matters

The filing is a routine corporate governance disclosure with no material financial impact.

02

Market read

Low relevance; typical governance filing with limited trading implications.

03

What to watch

Potential hidden strategic shifts if the director has industry connections.

Relevance 6/10Novelty 4/10Timing: today

Background

Immuneering Corp filed a Form 8‑K on Nov 9, 2026 announcing a board appointment.

Company-level read

Ticker impact

$IMRXNeutralHigh confidence
Context

SEC 8‑K filing reports appointment of Grant C. Bogle as a Class III director and related indemnification agreements.

Expected impact

likely neutral as market prices in the appointment with no material change to strategy.

Evidence & confidence

Director appointments are routine corporate governance events that rarely move share price.

Market effects

Minimal; governance change does not affect the broader biotech sector.

None; company is US‑listed and the filing is company‑specific.

None

Counterpoint

If the new director brings unique expertise, there could be a modest upside.

Key entities

  • Immuneering Corp

    Biotech firm listed on NASDAQ under IMRX.

  • Grant C. Bogle

    Appointed Class III director.

Related articles

$IMRXHigh

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

Immuneering Corp (IMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N

$IMRXMed

Immuneering presents phase 3 pancreatic cancer trial design

Immuneering Corporation (IMRX) presented its Phase 3 trial design for atebimetinib in pancreatic cancer at the European Society for Medical Oncology Congress. The global study compares atebimetinib with modified chemotherapy against standard treatment, with overall survival as the primary endpoint. The trial follows promising Phase 2a results and is currently recruiting patients.